相关实验视频
Updated: Jan 13, 2026

08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
16.8K
在肝纤维化中进行氧化调节:将NOX1/4抑制转化为治疗
Ghaith K Mansour1, Ahmad W Hajjar2, Irene Marafini3,4
1College of Pharmacy, Alfaisal University, Riyadh P.O. Box 50927, Saudi Arabia.
International journal of molecular sciences
|January 10, 2026
概括
塞塔纳西布是一种新型NOX1/4抑制剂,通过减少肝纤维化来治疗慢性肝病 (CLD) 是有前途的. 临床试验表明,患者的疲劳和生活质量可能有所改善.
科学领域:
- 肝病学和降解毒素生物学
- 药理学和药物开发领域
背景情况:
- 慢性肝病 (CLD),包括MASLD和PBC,是一个重要的全球健康挑战,治疗方法有限.
- 肝纤维化是CLD的常见途径,由尼古丁胺氨酸二核酸酸氧化酶 (NOX) 介导的氧化应激驱动.
研究的目的:
- 审查分子药理学,临床前数据和选择性NOX1/4抑制剂塞塔纳西布的临床结果.
- 评估针对NOX1/4轴治疗肝纤维化的治疗潜力.
主要方法:
- 对NOX1/4轴药理学当前知识的综合.
- 对塞塔纳西布的临床前翻译模型和临床试验数据的审查.
- 检查塞塔纳西布对肝星细胞激活,ECM沉积和巨细胞极化的影响.
主要成果:
- 塞塔纳克西布通过减弱关键的纤维基因通路来显示 pleotropic 抗纤维菌作用.
- 该药物表现出有利的药理动力学和良好的安全性概况,主要胆道胆炎 (PBC) 的患者.
- 新出现的证据表明,塞塔纳克西布可以改善PBC患者的疲劳和生活质量.
结论:
- 用塞塔纳西布向抑制NOX是一种有前途的肝纤维化治疗策略.
- 进一步的研究,包括人工智能驱动的预测建模,可以优化患者分层和治疗反应.
- 塞塔纳克西布为氧化还原向肝保护疗法提供了潜在的新途径.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
210
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
210
Peroxisomes
19.9K
Peroxisomes are specialized organelles present in fungi, plant, and animal cells. It can vary in number, size, morphology, and activity depending on the type of tissue and the nutritional state of the cell. For example, cells with active lipid metabolism, such as adipocytes, neurons, and hepatocytes, have more peroxisomes than other cells in the body. Besides their primary role in breaking down complex organic molecules, peroxisomes can also synthesize specific macromolecules and participate in...
19.9K
